1993
DOI: 10.1016/0006-2952(93)90632-7
|View full text |Cite
|
Sign up to set email alerts
|

Thiazolidine derivatives as source of free l-cysteine in rat tissue

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
21
0

Year Published

1994
1994
2014
2014

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 32 publications
(22 citation statements)
references
References 53 publications
1
21
0
Order By: Relevance
“…The neutral pH and relatively low concentrations of cysteine found in the cell may prevent MTD from being formed (29), especially when RidA is present. Furthermore, the physiological relevance of MTD in any organism remains unclear (21,51). However, there is interest in the use of thiazolidine derivatives in therapeutic applications (21).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…The neutral pH and relatively low concentrations of cysteine found in the cell may prevent MTD from being formed (29), especially when RidA is present. Furthermore, the physiological relevance of MTD in any organism remains unclear (21,51). However, there is interest in the use of thiazolidine derivatives in therapeutic applications (21).…”
Section: Resultsmentioning
confidence: 99%
“…Furthermore, the physiological relevance of MTD in any organism remains unclear (21,51). However, there is interest in the use of thiazolidine derivatives in therapeutic applications (21). MTD and other thiazolidine derivatives can be converted to cysteine nonenzymatically or enzymatically and are viewed as a means of delivering adequate doses of cysteine to mammalian systems without causing cysteine toxicity (21).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Such cysteine prodrugs include N-acetyl-L-cysteine (NAC) (Vinfi et al, 1980;Lauterburg et al, 1983;Ruffman and Wendel, 199l;Traber et al, 1992;Yao et al, 1994), L-2-oxothiazolidine-4-carboxylate (OTC) (Williamson et al, 1982;Porta et al, 1991), and condensation products of L-cysteine and reducing monosaccharides (Roberts et al, 1987) such as 2-(D-gluco-pentahydroxypentyl)-thiazolidine-4-carboxylic acid (D-glucose-L-cysteine, glc-cys) (Roberts et al, 1987;Gomez et al, 1994) and 2-(D-ribo-tetrahydroxybutyl)thiazolidine-4-carboxylic acid (D-ribose-L-cysteine, rib-cys) (Roberts et al, 1992). Condensation products of L-cysteine and carbonyl compounds have also been shown to act as cysteine prodrugs (Wt'odek et al, 1993). However, only a few papers on the glc-cys as a cysteine prodrug (Roberts et al, 1987;Gomez et al, 1994) have been reported.…”
Section: Introductionmentioning
confidence: 97%